Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

Incyte and Pharmasset enter Reverset licensing agreement

Sep. 10, 2003

Serostim E.U. appeal results in second negative opinion

Sep. 10, 2003

Continuation of phase I VRX-496 trial recommended

Sep. 9, 2003

Promising anti-HIV agent targets HIV-1 envelope protein

Sep. 8, 2003

Microbicide UC-781 enters phase I

Sep. 8, 2003

Phase I trial evaluates safety of AMD-070 for treatment of HIV infection

Sep. 8, 2003

Efficacy of oral recombinant L. lactis vector expressing the HIV Env gene as an HIV vaccine in mice

Sep. 5, 2003

Full approval for Serostim in AIDS wasting

Sep. 3, 2003

Alert issued on Reyataz in combination with Viread

Sep. 2, 2003

New HIV integrase inhibitors in early development at Merck

Sep. 2, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...